What makes a good anti-inflammatory drug target?

The recent, rapid increase in the number of defined targets in the immune system will ensure a rich stream of future anti-inflammatory drug targets. This review focuses on the major, ‘successful’ target families in inflammation and attempts to identify some of the key features of what makes a good a...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2006-03, Vol.11 (5-6), p.210-219
Main Author: Simmons, David L.
Format: Article
Language:English
Subjects:
adhesion molecules
Anti-Inflammatory Agents - pharmacology
Anti-Inflammatory Agents - therapeutic use
Antigens, Surface - physiology
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Cell Adhesion Molecules - physiology
cytokine
Cytokines - physiology
Cytokines - therapeutic use
General pharmacology
GPCR
Humans
inflammation
interleukin
Interleukins - physiology
Interleukins - therapeutic use
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Receptors, G-Protein-Coupled - drug effects
Receptors, G-Protein-Coupled - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent, rapid increase in the number of defined targets in the immune system will ensure a rich stream of future anti-inflammatory drug targets. This review focuses on the major, ‘successful’ target families in inflammation and attempts to identify some of the key features of what makes a good anti-inflammatory target. The review is based on a systematic analysis of approved anti-inflammatory drugs grouped according to their drug–target family. The cytokine family is a drug-dense area. They have yielded and continue to yield a rich stream of drugs. As in other therapeutic areas, G-protein-coupled receptors (GPCRs), also known as seven-transmembrane pass receptors, have provided significant drug targets. In addition, the superfamilies of cell adhesion molecules and co-stimulatory molecules, which have special relevance to immune processes, have begun to provide the first approved drugs and might yield many more. The recent, rapid increase in the number of defined targets in the immune system – leukocyte surface antigens, cytokines, GPCRs, adhesion molecules and co-stimulatory molecules – will ensure a rich stream of future anti-inflammatory drug targets.
ISSN:1359-6446
1878-5832
DOI:10.1016/S1359-6446(05)03721-9